Boston Scientific EBITDA Margin 2010-2025 | BSX
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Boston Scientific (BSX) over the last 10 years. The current EBITDA margin for Boston Scientific as of March 31, 2025 is .
| Boston Scientific EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2025-03-31 | $17.55B | $4.53B | 25.81% |
| 2024-12-31 | $16.75B | $4.26B | 25.44% |
| 2024-09-30 | $15.91B | $4.02B | 25.28% |
| 2024-06-30 | $15.23B | $3.98B | 26.11% |
| 2024-03-31 | $14.71B | $3.74B | 25.42% |
| 2023-12-31 | $14.24B | $3.60B | 25.26% |
| 2023-09-30 | $13.76B | $3.39B | 24.66% |
| 2023-06-30 | $13.40B | $3.17B | 23.63% |
| 2023-03-31 | $13.05B | $2.99B | 22.95% |
| 2022-12-31 | $12.68B | $2.92B | 22.99% |
| 2022-09-30 | $12.57B | $2.89B | 22.97% |
| 2022-06-30 | $12.33B | $2.91B | 23.58% |
| 2022-03-31 | $12.16B | $2.78B | 22.87% |
| 2021-12-31 | $11.89B | $2.66B | 22.38% |
| 2021-09-30 | $11.47B | $2.42B | 21.06% |
| 2021-06-30 | $11.20B | $1.89B | 16.91% |
| 2021-03-31 | $10.12B | $1.61B | 15.88% |
| 2020-12-31 | $9.91B | $1.58B | 15.91% |
| 2020-09-30 | $10.11B | $1.37B | 13.50% |
| 2020-06-30 | $10.16B | $1.48B | 14.60% |
| 2020-03-31 | $10.79B | $1.58B | 14.68% |
| 2019-12-31 | $10.74B | $1.52B | 14.13% |
| 2019-09-30 | $10.39B | $1.63B | 15.65% |
| 2019-06-30 | $10.08B | $1.63B | 16.19% |
| 2019-03-31 | $9.94B | $1.64B | 16.49% |
| 2018-12-31 | $9.82B | $1.51B | 15.33% |
| 2018-09-30 | $9.67B | $1.51B | 15.58% |
| 2018-06-30 | $9.50B | $1.50B | 15.74% |
| 2018-03-31 | $9.27B | $1.33B | 14.34% |
| 2017-12-31 | $9.05B | $1.29B | 14.20% |
| 2017-09-30 | $8.83B | $1.11B | 12.53% |
| 2017-06-30 | $8.71B | $1.08B | 12.36% |
| 2017-03-31 | $8.58B | $0.52B | 6.04% |
| 2016-12-31 | $8.39B | $0.45B | 5.33% |
| 2016-09-30 | $8.17B | $0.08B | 0.98% |
| 2016-06-30 | $7.96B | $-0.57B | -7.13% |
| 2016-03-31 | $7.67B | $-0.01B | -0.18% |
| 2015-12-31 | $7.48B | $-0.28B | -3.78% |
| 2015-09-30 | $7.39B | $-0.55B | -7.43% |
| 2015-06-30 | $7.34B | $-0.19B | -2.53% |
| 2015-03-31 | $7.37B | $-0.47B | -6.43% |
| 2014-12-31 | $7.38B | $-0.30B | -4.08% |
| 2014-09-30 | $7.33B | $0.32B | 4.35% |
| 2014-06-30 | $7.22B | $0.36B | 4.96% |
| 2014-03-31 | $7.16B | $0.65B | 9.04% |
| 2013-12-31 | $7.14B | $0.12B | 1.68% |
| 2013-09-30 | $7.13B | $0.11B | 1.54% |
| 2013-06-30 | $7.13B | $-0.59B | -8.24% |
| 2013-03-31 | $7.14B | $-4.39B | -61.51% |
| 2012-12-31 | $7.25B | $-3.87B | -53.36% |
| 2012-09-30 | $7.28B | $-3.81B | -52.41% |
| 2012-06-30 | $7.42B | $-3.05B | -41.07% |
| 2012-03-31 | $7.56B | $0.78B | 10.29% |
| 2011-12-31 | $7.62B | $0.90B | 11.86% |
| 2011-09-30 | $7.78B | $1.08B | 13.90% |
| 2011-06-30 | $7.82B | $1.16B | 14.81% |
| 2011-03-31 | $7.77B | $1.15B | 14.82% |
| 2010-12-31 | $7.81B | $-0.66B | -8.40% |
| 2010-09-30 | $7.88B | $-2.24B | -28.35% |
| 2010-06-30 | $7.99B | $-2.44B | -30.47% |
| 2010-03-31 | $8.14B | $-2.39B | -29.38% |
| 2009-12-31 | $8.19B | $-0.89B | -10.92% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $153.093B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $228.771B | 27.51 |
| Stryker (SYK) | United States | $149.084B | 31.17 |
| EssilorLuxottica (ESLOY) | France | $130.144B | 0.00 |
| Medtronic (MDT) | Ireland | $114.429B | 16.22 |
| Lonza Group Ag (LZAGY) | Switzerland | $49.231B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.710B | 24.95 |
| ResMed (RMD) | United States | $36.952B | 27.75 |
| GE HealthCare Technologies (GEHC) | United States | $34.062B | 16.17 |
| Agilent Technologies (A) | United States | $32.082B | 20.92 |
| Terumo (TRUMY) | Japan | $24.207B | 31.44 |
| Koninklijke Philips (PHG) | Netherlands | $23.216B | 16.29 |
| Insulet (PODD) | United States | $20.408B | 80.11 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.604B | 11.95 |
| Baxter (BAX) | United States | $14.497B | 10.82 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.846B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.731B | 23.42 |
| Lantheus Holdings (LNTH) | United States | $5.622B | 14.18 |
| Perrigo (PRGO) | Ireland | $3.719B | 9.43 |
| Prestige Consumer Healthcare (PBH) | United States | $3.714B | 16.59 |
| Haemonetics (HAE) | United States | $3.585B | 16.33 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.358B | 27.90 |
| ICU Medical (ICUI) | United States | $3.113B | 22.96 |
| QuidelOrtho (QDEL) | United States | $1.890B | 13.00 |
| LeMaitre Vascular (LMAT) | United States | $1.858B | 41.53 |
| AtriCure (ATRC) | United States | $1.512B | 0.00 |
| Acuren (TIC) | United States | $1.407B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.245B | 28.00 |
| Phibro Animal Health (PAHC) | United States | $1.239B | 15.83 |
| AdaptHealth (AHCO) | United States | $1.205B | 12.23 |
| Neogen (NEOG) | United States | $1.079B | 13.81 |
| BioLife Solutions (BLFS) | United States | $0.994B | 0.00 |
| InMode (INMD) | Israel | $0.901B | 9.08 |
| Kestra Medical Technologies (KMTS) | United States | $0.836B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.670B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.660B | 0.00 |
| Owens & Minor (OMI) | United States | $0.600B | 4.98 |
| Evolus (EOLS) | United States | $0.598B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.597B | 0.00 |
| CeriBell (CBLL) | United States | $0.569B | 0.00 |
| Valneva SE (VALN) | France | $0.549B | 0.00 |
| Surmodics (SRDX) | United States | $0.448B | 0.00 |
| SNDL (SNDL) | Canada | $0.397B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.328B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.318B | 11.71 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.285B | 0.00 |
| Quanterix (QTRX) | United States | $0.274B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.262B | 22.07 |
| Cresco Labs (CRLBF) | United States | $0.258B | 0.00 |
| Cerus (CERS) | United States | $0.258B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.252B | 74.83 |
| ZimVie (ZIMV) | United States | $0.246B | 11.19 |
| Sanara MedTech (SMTI) | United States | $0.242B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.233B | 0.00 |
| Brainsway (BWAY) | Israel | $0.231B | 61.00 |
| Biote (BTMD) | United States | $0.216B | 6.06 |
| Omeros (OMER) | United States | $0.212B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.200B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.199B | 0.00 |
| Organigram Global (OGI) | Canada | $0.192B | 0.00 |
| High Tide (HITI) | Canada | $0.188B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.182B | 14.80 |
| TriSalus Life Sciences (TLSI) | United States | $0.179B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.155B | 0.00 |
| Exagen (XGN) | United States | $0.144B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.124B | 15.25 |
| TerrAscend (TSNDF) | Canada | $0.107B | 0.00 |
| Jin Medical (ZJYL) | China | $0.100B | 0.00 |
| Fonar (FONR) | United States | $0.099B | 12.80 |
| MacroGenics (MGNX) | United States | $0.094B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.087B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.085B | 0.00 |
| Veru (VERU) | United States | $0.085B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.080B | 0.00 |
| Apyx Medical (APYX) | United States | $0.077B | 0.00 |
| Zynex (ZYXI) | United States | $0.069B | 0.00 |
| Agape ATP (ATPC) | $0.069B | 0.00 | |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.064B | 0.00 |
| ImmuCell (ICCC) | United States | $0.057B | 0.00 |
| United-Guardian (UG) | United States | $0.042B | 14.41 |
| Modular Medical (MODD) | United States | $0.038B | 0.00 |
| Nephros (NEPH) | United States | $0.037B | 50.43 |
| Rockwell Medical (RMTI) | United States | $0.037B | 0.00 |
| Safety Shot (SHOT) | United States | $0.032B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.024B | 0.00 |
| Flora Growth (FLGC) | United States | $0.015B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |